{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T08:16:14Z","timestamp":1793866574798,"version":"4.6.1"},"reference-count":30,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"9","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precis Oncol"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>PURPOSE<\/jats:title>\n            <jats:p>\n              ORCHARD (ClinicalTrials.gov identifier:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03944772\">NCT03944772<\/jats:ext-link>\n              ) is a phase II, biomarker-directed platform study designed to characterize resistance mechanisms and evaluate novel drug combinations in patients with epidermal growth factor receptor (\n              <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n              )\u2013mutated advanced non\u2013small cell lung cancer who have progressed on first-line osimertinib. We report final results of the module assessing the efficacy and safety of osimertinib plus necitumumab (a monoclonal antibody that blocks EGFR) in patients with \u2265one of the following:\n              <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n              amplification or select secondary\n              <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n              alterations (L718 or G724 mutation, or exon 20 insertion).\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MATERIALS AND METHODS<\/jats:title>\n            <jats:p>Patients received osimertinib (80 mg orally once daily) plus necitumumab (800 mg intravenously, days 1 and 8 of a 3-week cycle) until disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR) per RECIST 1.1 by investigator assessment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>\n              Overall, 19 patients received osimertinib plus necitumumab; at data cutoff (April 18, 2023), all patients had discontinued treatment. The ORR was 11% (80% CI, 3 to 26); two patients had a confirmed partial response, with duration of response of 10.4 and 6.0 months; both patients had\n              <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n              amplification. The median progression-free survival was 4.0 months (95% CI, 1.3 to 5.4) and the overall survival was 11.4 months (95% CI, 6.6 to 15.5). Ten patients (53%) had grade \u22653 adverse events, most commonly embolism (not otherwise specified, pulmonary embolism or deep vein thrombosis, reported in four patients; 21%). The safety profile of the combination was consistent with the known profiles of the two individual drugs, and no new signals were identified.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>Osimertinib plus necitumumab demonstrated modest clinical benefit, and the overall risk-benefit analysis indicates that further evaluation of the regimen is not warranted in these molecularly defined subsets of osimertinib resistance.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1200\/po-24-00818","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:59:18Z","timestamp":1749067158000},"update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":11,"title":["ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor\u2013Mutated Advanced Non\u2013Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib"],"prefix":"10.1200","clinical-trial-number":[{"clinical-trial-number":"nct03944772","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7370-7304","authenticated-orcid":true,"given":"Jonathan W.","family":"Riess","sequence":"first","affiliation":[{"name":"UC Davis Comprehensive Cancer Center, Sacramento, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7343-633X","authenticated-orcid":true,"given":"Adrianus J.","family":"de Langen","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Ponce","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitario and Centro Nacional de Investigaciones Oncologicas, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0920-1381","authenticated-orcid":true,"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Medicine (Medical Oncology), Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9008-8573","authenticated-orcid":true,"given":"Zofia","family":"Piotrowska","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4925-8243","authenticated-orcid":true,"given":"Jonathan W.","family":"Goldman","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8554-1185","authenticated-orcid":true,"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[{"name":"Thoracic Head and Neck Medical Oncology Department, MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-270X","authenticated-orcid":true,"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuto","family":"Yoneshima","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Early Oncology, Oncology R&amp;D, AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cavazzina","sequence":"additional","affiliation":[{"name":"Fortrea Development Limited, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7729-5159","authenticated-orcid":true,"given":"Kwan Ho","family":"Tang","sequence":"additional","affiliation":[{"name":"Translational Medicine, Oncology R&amp;D, AstraZeneca, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lau","sequence":"additional","affiliation":[{"name":"Early Development, AstraZeneca, Gaithersburg, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-9510","authenticated-orcid":true,"given":"Helena A.","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York City, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_10_2_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"e_1_3_10_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_3_10_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_3_10_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071"},{"key":"e_1_3_10_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9363"},{"key":"e_1_3_10_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118"},{"key":"e_1_3_10_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_3_10_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_3_10_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01055"},{"key":"e_1_3_10_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02133"},{"key":"e_1_3_10_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8"},{"key":"e_1_3_10_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-35961-y"},{"key":"e_1_3_10_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.398"},{"key":"e_1_3_10_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.02.025"},{"key":"e_1_3_10_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2007.11.009"},{"key":"e_1_3_10_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.9014"},{"key":"e_1_3_10_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.06.006"},{"key":"e_1_3_10_19_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3146"},{"key":"e_1_3_10_20_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0326"},{"key":"e_1_3_10_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.117"},{"key":"e_1_3_10_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.823"},{"key":"e_1_3_10_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2014.06.005"},{"key":"e_1_3_10_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2016-000252"},{"key":"e_1_3_10_25_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10390-0"},{"key":"e_1_3_10_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx703"},{"key":"e_1_3_10_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.354"},{"key":"e_1_3_10_28_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587"},{"key":"e_1_3_10_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt205"},{"key":"e_1_3_10_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/pst.1746"},{"key":"e_1_3_10_31_2","volume-title":"WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart","author":"Travis WB","year":"2015","unstructured":"Travis WB, Brambilla E, Burke AP, et al. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. ed 4. Lyon, France: IARC Publications; 2015:Volume 7.","edition":"4"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO-24-00818","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T19:59:21Z","timestamp":1749067161000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO-24-00818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1200\/PO-24-00818"],"URL":"https:\/\/doi.org\/10.1200\/po-24-00818","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2400818"}}